---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Pharmacodynamics"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Pharmacodynamics. Topics: Viral replication and GM-CSF expression in urine during induction, BOND-003 Cohort C; Replication and transgene expression during maintenance dosing, BOND-003 Cohort C; Adenovirus serotype 5 antibodies and antibody response over time, BOND-003 Cohort C; Urinary cytokine profiling as a measure of the local immune response, BOND-003 Cohort C; 5 further topics. 9 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Viral replication and GM-CSF expression in urine during induction, BOND-003 Cohort C

> “Cretostimogene replication and GM-CSF expression are linked”
> “Levels peak immediately after instillation”
> “Sustained local dosing”
> “Drop to BLOD within a week”
> “Effective payload delivery”

Source: [Bivalacqua (2025)](https://cgoncology.com/wp-content/uploads/2025/11/Updated_Clinical_and_Translational_Results_from_BOND-003_Cohort_C.pdf)

<a id="topic-2.1.2.6.2-2"></a>

### Replication and transgene expression during maintenance dosing, BOND-003 Cohort C

> “Similar pharmacokinetic peak and trough pattern, that mirrors replication kinetics”
> “Titers present through maintenance”
> “Supports oncolytic immunotherapy MOA”

Source: [Bivalacqua (2025)](https://cgoncology.com/wp-content/uploads/2025/11/Updated_Clinical_and_Translational_Results_from_BOND-003_Cohort_C.pdf)

<a id="topic-2.1.2.6.2-3"></a>

### Adenovirus serotype 5 antibodies and antibody response over time, BOND-003 Cohort C

> “Pre-existing Ad5 antibodies”
> “Stable antibody and anti-tumor response over time”
> “Antibody response correlates with clinical outcomes”
> “Intravesical delivery reduces ADA neutralization, preserving therapeutic efficacy”

Source: [Bivalacqua (2025)](https://cgoncology.com/wp-content/uploads/2025/11/Updated_Clinical_and_Translational_Results_from_BOND-003_Cohort_C.pdf)

<a id="topic-2.1.2.6.2-4"></a>

### Urinary cytokine profiling as a measure of the local immune response, BOND-003 Cohort C

> “Urinary cytokines (a surrogate of local immune milieu) were profiled post-treatment to characterize the immune-mediated MOA”
> “Serial urine collected pre-dose (−2 hr) and post-dose (+2 hr) across treatment phases from BOND-003 Cohort C biomarker consented participants (n=60)”
> “Tested with Olink Target 48 Cytokine panel”

Source: [Dinney et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_and_Cytokines_Poster.pdf)

<a id="topic-2.1.2.6.2-5"></a>

### Magnitude and direction of the urinary cytokine changes during induction

> “GM-CSF (CSF2) shows the largest induction (~300-fold peak at W1 D4).”
> “Coordinated induction of Th1, Th17, M1, DC-priming, and TNF-superfamily analytes is evident at post-dose timepoints.”
> “Th2 and immunoregulatory cytokines remained largely below the limit of detection and were not induced.”
> “Post-dose induction with return toward baseline before subsequent dosing indicates repeated acute, self-limiting immune activation.”

Source: [Dinney et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_and_Cytokines_Poster.pdf)

<a id="topic-2.1.2.6.2-6"></a>

### GM-CSF transgene expression and replication in the phase 1 study

> “High levels of granulocyte-monocyte colony-stimulating factor were detected in urine after administration in all patients.”
> “Virus replication was suggested based on an increase in urine CG0070 genomes between days 2 and 5 in 58.3% of tested patients (7 of 12).”
> “Granulocyte-monocyte colony-stimulating factor transgene expression and CG0070 replication were also suggested.”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="topic-2.1.2.6.2-7"></a>

### Retinoblastoma phosphorylation status and response in the phase 1 study

> “A subset of 18 patients was assessed for retinoblastoma phosphorylation status.”
> “In an exploratory, retrospective assessment patients with borderline or high retinoblastoma phosphorylation who received the multidose schedules had an 81.8% complete response rate (9 of 11).”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="topic-2.1.2.6.2-8"></a>

### Urinary tumor DNA minimal residual disease in BOND-003 and CORE-001

> “UroAmp is Convergent Genomics’s genetic platform which quantifies mutations and DNA alterations from urine tumor DNA (utDNA).”
> “Quantifies minimal residual disease (MRD) by the genomic disease burden (GDB) which is a percentile ranking of the variant allele frequency (VAF) from a sample relative to its percentile ranking within the established training set.”
> “VAF and MRD prognostic for recurrence.”
> “UroAmp stratified patients treated with Cretostimogene as MRD positive or negative and was associated with durable 12 mo. RFS.”

Source: [Mokkapati (2025)](https://cgoncology.com/wp-content/uploads/2025/11/A0793_Mokkapati_EAU-2025_BOND-003-and-CORE-001-Convergent_Final-V7-1.pdf)

<a id="topic-2.1.2.6.2-9"></a>

### Pretreatment PD-L1 expression and response in muscle-invasive disease, CORE-002

> “Importantly, investigators found that treatment response was not correlated with pre-treatment PD-L1 levels, and that the majority of PD-L1 negative patients had CRs.”
> “Additionally, the formation and maturation of tertiary lymphoid structure (TLS) in responders were observed, suggesting the mechanistic onset of anti-tumor humoral memory.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
